HYPOGAMMAGLOBULINEMIA
Clinical trials for HYPOGAMMAGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new HYPOGAMMAGLOBULINEMIA trials appear
Sign up with your email to follow new studies for HYPOGAMMAGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot may shield myeloma patients from deadly infections
Disease control Recruiting nowThis study tests whether a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels due to treatment with bispecific antibodies. About 100 participants will either receive IgPro20 or standard care, and researchers will compa…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for blood cancer patients: drug aims to cut Life-Threatening infections
Prevention Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks along with standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody le…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Prevention
Last updated May 17, 2026 11:37 UTC
-
MS fatigue mystery: could low antibodies be the hidden cause?
Knowledge-focused Recruiting nowThis study looks at whether low levels of immunoglobulins (antibodies) are a treatable cause of fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue levels and infection rates between MS patients with and without low antibody levels. The goal is to und…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC